Published in Sex Transm Dis on March 01, 2009
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology (2010) 1.41
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24
Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res (2010) 1.15
Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation. J Immunol (2010) 1.01
Advances in the Development of Microbicides for the Prevention of HIV Infection. Curr Infect Dis Rep (2010) 0.99
Development of an in vitro alternative assay method for vaginal irritation. Toxicology (2010) 0.87
Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collection. PLoS One (2013) 0.86
Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One (2012) 0.82
Quantitative assessment of microbicide-induced injury in the ovine vaginal epithelium using confocal microendoscopy. BMC Infect Dis (2012) 0.82
Advances in HIV microbicide development. Future Med Chem (2011) 0.81
Minocycline down-regulates topical mucosal inflammation during the application of microbicide candidates. PLoS One (2012) 0.80
Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS One (2015) 0.80
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob Agents Chemother (2012) 0.80
Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. PLoS One (2016) 0.78
Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya. PLoS One (2014) 0.77
Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl) (2013) 0.77
Recruitment of HIV-1 target cells at topical mucosal sites: a sensitive and early marker for determining the safety of microbicide candidates. Emerg Microbes Infect (2013) 0.75
Effects of Female Sex Hormones on Susceptibility to HSV-2 in Vaginal Cells Grown in Air-Liquid Interface. Viruses (2016) 0.75
Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus. Biomacromolecules (2014) 0.75
Use of laptop computers connected to internet through Wi-Fi decreases human sperm motility and increases sperm DNA fragmentation. Fertil Steril (2011) 2.95
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Amino acid conjugated sophorolipids: A new family of biologically active functionalized glycolipids. Bioconjug Chem (2006) 2.01
As the world grows: contraception in the 21st century. J Clin Invest (2008) 1.37
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol (2011) 1.33
Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses (2012) 1.23
Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr (2014) 1.23
Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl (2002) 1.23
Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio (2011) 1.21
Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV. Contraception (2007) 1.19
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res (2010) 1.15
Sophorolipids, microbial glycolipids with anti-human immunodeficiency virus and sperm-immobilizing activities. Antimicrob Agents Chemother (2005) 1.12
Twice-daily application of HIV microbicides alter the vaginal microbiota. MBio (2012) 1.11
Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies. Antiviral Res (2010) 1.10
Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One (2011) 1.08
Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate). Biol Reprod (2002) 1.07
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health (2013) 1.05
Biomarkers of leukocyte traffic and activation in the vaginal mucosa. Biomarkers (2007) 1.01
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology (2008) 0.97
Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. J Med Chem (2012) 0.95
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol (2014) 0.93
Emtricitabine prodrugs with improved anti-HIV activity and cellular uptake. Mol Pharm (2012) 0.92
Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. AIDS Res Hum Retroviruses (2013) 0.92
High cholesterol content and decreased membrane fluidity in human spermatozoa are associated with protein tyrosine phosphorylation and functional deficiencies. J Androl (2009) 0.91
Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr (2008) 0.91
Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine. Bioorg Med Chem Lett (2011) 0.90
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Microbicides 2008 conference: from discovery to advocacy. AIDS Res Ther (2008) 0.88
Coprecipitation of nonoxynol-9 with polyvinylpyrrolidone to decrease vaginal irritation potential while maintaining spermicidal potency. AAPS PharmSciTech (2003) 0.86
Effect of diltiazem and methylene blue on human sperm motility, viability and cervical mucus penetration: potential use as vas irrigants at the time of vasectomy. Contraception (2003) 0.86
Induction of cyclooxygenase (COX)-2 in human vaginal epithelial cells in response to TLR ligands and TNF-α. Am J Reprod Immunol (2012) 0.86
Non-specific microbicide product development: then and now. Curr HIV Res (2012) 0.85
Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors. J Med Chem (2012) 0.84
Improved endometrial assessment using cyclin E and p27. Fertil Steril (2003) 0.84
Effect of thawing temperature on the motility recovery of cryopreserved human spermatozoa. Fertil Steril (2008) 0.84
A hierarchy of lipid constructs for the sperm plasma membrane. Biochem Biophys Res Commun (2003) 0.83
A structure-activity study of spermicidal and anti-HIV properties of hydroxylated cationic surfactants. Bioorg Med Chem (2002) 0.83
A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. Int J Antimicrob Agents (2008) 0.82
Synthesis, antiviral and contraceptive activities of nucleoside-sodium cellulose sulfate acetate and succinate conjugates. Bioorg Med Chem Lett (2010) 0.82
Biomarker discovery: validation and decision-making in product development. Sex Transm Dis (2009) 0.82
Capacitation-associated changes in membrane fluidity in asthenozoospermic human spermatozoa. Int J Androl (2008) 0.81
Capacitation-associated protein tyrosine phosphorylation and membrane fluidity changes are impaired in the spermatozoa of asthenozoospermic patients. Reproduction (2005) 0.81
Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection. Am J Reprod Immunol (2011) 0.80
Incidence of sperm-tail tyrosine phosphorylation and hyperactivated motility in normozoospermic and asthenozoospermic human sperm samples. Biocell (2003) 0.80
Comparing anti-HIV, antibacterial, antifungal, micellar, and cytotoxic properties of tricarboxylato dendritic amphiphiles. Bioorg Med Chem (2009) 0.79
Cyclic nucleotide phosphodiesterase inhibition increases tyrosine phosphorylation and hyper motility in normal and pathological human spermatozoa. Biocell (2005) 0.78
Preclinical evaluation of UC781 microbicide vaginal drug delivery. Drug Deliv Transl Res (2011) 0.78
Superoxide dismutase content in sperm correlates with motility recovery after thawing of cryopreserved human spermatozoa. Fertil Steril (2011) 0.78
TSPY4 is a novel sperm-specific biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and contraception studies. Contraception (2012) 0.78
Seminal plasma induces prostaglandin-endoperoxide synthase (PTGS) 2 expression in immortalized human vaginal cells: involvement of semen prostaglandin E2 in PTGS2 upregulation. Biol Reprod (2013) 0.78
Impact of membrane cholesterol content on the resistance of vesicles to surfactant attack. Langmuir (2005) 0.77
Design, synthesis, antiviral activity, and pre-formulation development of poly-L-arginine-fatty acyl derivatives of nucleoside reverse transcriptase inhibitors. Nucleosides Nucleotides Nucleic Acids (2015) 0.77
Comparison of visual and ultraviolet light inspection versus DNA/protein biomarkers to assess product adherence with vaginal microbicide applicators. Sex Transm Dis (2014) 0.76
Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues. J Acquir Immune Defic Syndr (2016) 0.75
Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques. Drug Deliv Transl Res (2015) 0.75
Anti-HIV activities of precisely defined, semirigid, carboxylated alternating copolymers. J Med Chem (2014) 0.75
Synthesis and anti-HIV activities of suramin conjugates of 3'-fluoro- 2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine. Med Chem (2012) 0.75